Inclusion Criteria:

          -  Documented informed consent of the participant and/or legally authorized
             representative. Assent, when appropriate, will be obtained per institutional
             guidelines

          -  Agreement to allow the use of archival tissue from diagnostic tumor biopsies. If
             unavailable, exceptions may be granted with study principal investigator (PI) approval

          -  Karnofsky performance status (KPS) >= 60%

          -  Eastern Cooperative Oncology Group (ECOG) =< 2

          -  Life expectancy >= 4 weeks

          -  Participant has a prior histologically-confirmed diagnosis of a grade IV glioblastoma,
             or has a prior histologically-confirmed diagnosis of a grade II or III malignant
             glioma and now has radiographic progression consistent with a grade IV glioblastoma

          -  Relapsed disease: radiographic evidence of recurrence/progression of measurable
             disease after standard therapy, and >= 12 weeks after completion of front-line
             radiation therapy

          -  City of Hope (COH) Clinical Pathology confirms matrix metalloproteinase (MMP)2+ tumor
             expression by immunohistochemistry (>= 20% moderate/high MMP2 [2+/3+])

          -  White blood cell (WBC) > 2000 /dl (or absolute neutrophil count [ANC] >= 1,000/mm^3)
             (to be performed within 14 days prior to leukapheresis unless otherwise stated)

          -  Platelets >= 75,000/mm^3 (to be performed within 14 days prior to leukapheresis unless
             otherwise stated)

          -  Hemoglobin >= 8 g/dl (to be performed within 14 days prior to leukapheresis unless
             otherwise stated)

          -  Total bilirubin =< 1.5 upper limit of normal (ULN) (to be performed within 14 days
             prior to leukapheresis unless otherwise stated)

          -  Aspartate aminotransferase (AST) =< 2.5 x ULN (to be performed within 14 days prior to
             leukapheresis unless otherwise stated)

          -  Alanine aminotransferase (ALT) =< 2.5 x ULN (to be performed within 14 days prior to
             leukapheresis unless otherwise stated)

          -  Serum creatinine =< 1.6 mg/dL (to be performed within 14 days prior to leukapheresis
             unless otherwise stated)

          -  Oxygen (O2) saturation >= 95% on room air (to be performed within 14 days prior to
             leukapheresis unless otherwise stated)

          -  Seronegative for human immunodeficiency virus (HIV) antigen (Ag)/antibody (Ab) combo
             (to be performed within 14 days prior to leukapheresis unless otherwise stated)

          -  Women of childbearing potential (WOCBP): negative urine or serum pregnancy test (to be
             performed within 14 days prior to leukapheresis unless otherwise stated)

               -  If the urine test is positive or cannot be confirmed as negative, a serum
                  pregnancy test will be required

          -  Agreement by females and males of childbearing potential* to use an effective method
             of birth control or abstain from heterosexual activity for the course of the study
             through at least 3 months after the last dose of CAR T cells

               -  Childbearing potential defined as not being surgically sterilized (men and women)
                  or have not been free from menses for > 1 year (women only)

        Exclusion Criteria:

          -  Owing to higher frequency of wound-related complications, participants who have had
             prior bevacizumab therapy are excluded

          -  Participant has not yet recovered from toxicities of prior therapy

          -  Uncontrolled seizure activity and/or clinically evident progressive encephalopathy

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to study agent

          -  Active diarrhea

          -  Clinically significant uncontrolled illness

          -  Active infection requiring antibiotics

          -  Known history of immunodeficiency virus (HIV) or hepatitis B or hepatitis C infection

          -  Other active malignancy

          -  Females only: Pregnant or breastfeeding

          -  Any other condition that would, in the investigator's judgment, contraindicate the
             subject's participation in the clinical study due to safety concerns with clinical
             study procedures

          -  Prospective participants who, in the opinion of the investigator, may not be able to
             comply with all study procedures (including compliance issues related to
             feasibility/logistics)